FDA approves Roche's Avastin plus chemotherapy for treatment of advanced cervical cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) approved Avastin (bevacizumab) in combination with paclitaxel and cisplatin or paclitaxel and topotecan for the treatment of women with persistent, recurrent or metastatic carcinoma of the cervix.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Carcinoma | Cervical Cancer | Chemotherapy | Food and Drug Administration (FDA) | Pharmaceuticals | Women